Population
Preclinical models (serum, platelets, and rat aorta strips)
Design
Preclinical
Authors
Loading...
Does not support changing aspirin use; leaves open whether NO-donor hybrids offer clinical advantages pending human trials.
These novel NO-donor aspirins demonstrate both antiplatelet and vasodilatory properties in preclinical models, suggesting potential as an alternative to standard aspirin.
Lazzarato et al. (2009) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: